Renal · Cystic Kidney Diseases

Polycystic Kidney Disease (ARPKD)

USMLE2PANCE
7

Bets

The facts most likely to be tested

1

ARPKD is caused by a mutation in the PKHD1 gene which encodes for fibrocystin.

Confidence:
2

The classic presentation involves bilateral flank masses and oligohydramnios in a neonate, leading to Potter sequence.

Confidence:
3

Pulmonary hypoplasia secondary to oligohydramnios is the most common cause of neonatal mortality in ARPKD patients.

Confidence:
4

Renal pathology is characterized by fusiform dilation of the collecting ducts resulting in a 'sponge-like' appearance on histology.

Confidence:
5

Hepatic involvement is universal and manifests as congenital hepatic fibrosis, which leads to portal hypertension and esophageal varices.

Confidence:
6

Diagnosis is typically established via prenatal ultrasound showing enlarged, echogenic kidneys with poor corticomedullary differentiation.

Confidence:
7

Management of severe cases is primarily supportive and focuses on respiratory support for pulmonary hypoplasia and renal replacement therapy.

Confidence:

Vignette unlocked

A newborn is delivered at 36 weeks gestation via spontaneous vaginal delivery to a mother with limited prenatal care. Upon physical examination, the infant exhibits flattened facies, low-set ears, and limb deformities. The abdomen is distended with palpable bilateral flank masses. A bedside ultrasound reveals enlarged, hyperechoic kidneys with loss of normal corticomedullary architecture. The infant develops severe respiratory distress shortly after birth requiring mechanical ventilation.

What is the most likely diagnosis?

+Reveal answer

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

The vignette describes the classic triad of ARPKD: bilateral flank masses, renal ultrasound findings of enlarged echogenic kidneys, and Potter sequence (pulmonary hypoplasia, flattened facies, limb deformities) resulting from oligohydramnios.

Mo

Depth

Full handout

High yield triage

Etiology / Epidemiology

Autosomal recessive disorder caused by PKHD1 gene mutation; typically presents in neonates.

Clinical Manifestations

Presents with bilateral flank masses and Potter sequence (pulmonary hypoplasia, oligohydramnios).

Diagnosis

Prenatal ultrasound is the gold standard; shows enlarged, echogenic kidneys.

Treatment

Supportive care; aggressive blood pressure control and renal replacement therapy for end-stage disease.

Prognosis

High perinatal mortality; survivors often develop portal hypertension and hepatic fibrosis.

Full handout

Epidemiology & Etiology

ARPKD is a rare, severe genetic disorder inherited in an autosomal recessive pattern. It is caused by mutations in the PKHD1 gene which encodes for fibrocystin. It is almost exclusively diagnosed in the neonatal period or early infancy.

Pertinent Anatomy

The disease involves fusiform dilation of the renal collecting ducts. This leads to massive bilateral renal enlargement that compresses surrounding structures. Concurrently, the liver exhibits congenital hepatic fibrosis due to biliary dysgenesis.

Pathophysiology

The fibrocystin protein defect disrupts ciliary function in the renal tubules and biliary tree. This results in the formation of microscopic cysts that replace functional renal parenchyma. The resulting renal insufficiency and oligohydramnios lead to the classic Potter sequence.

Clinical Manifestations

Neonates present with bilateral flank masses and respiratory distress due to pulmonary hypoplasia. Physical exam reveals the Potter facies (low-set ears, flattened nose, micrognathia). Respiratory failure is the most common cause of early neonatal death.

Diagnosis

Prenatal ultrasound is the primary diagnostic tool, revealing bilaterally enlarged, hyperechoic kidneys. Postnatal confirmation is achieved via renal ultrasound showing loss of corticomedullary differentiation. Genetic testing for PKHD1 confirms the diagnosis in ambiguous cases.

Treatment

Management is primarily supportive, focusing on mechanical ventilation for pulmonary hypoplasia. ACE inhibitors are the first-line agents for managing systemic hypertension. Avoid nephrotoxic agents; patients may eventually require renal transplantation or dialysis.

Prognosis

The prognosis is poor, with a 30-50% mortality rate in the neonatal period. Survivors face long-term complications including portal hypertension and Caroli disease (biliary duct dilation). Regular monitoring of liver function and blood pressure is mandatory.

Differential Diagnosis

ADPKD: presents in adulthood with liver cysts and berry aneurysms

Multicystic dysplastic kidney: usually unilateral and non-hereditary

Congenital nephrotic syndrome: presents with massive proteinuria and edema

Renal vein thrombosis: presents with hematuria and thrombocytopenia

Wilms tumor: usually a unilateral solid mass, not cystic